Nanomix Corporation (NNMX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nanomix Corporation (NNMX) trades at $0.0002. Nanomix Corporation, formerly Boston Therapeutics, Inc. , focuses on developing and commercializing therapeutic drugs and diagnostic tools for diabetes and inflammatory diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for NNMX: NNMX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NNMX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NNMX.
How is this calculated? →Nanomix Corporation (NNMX) Healthcare & Pipeline Overview
Nanomix Corporation (NNMX) is a healthcare company focused on developing and commercializing therapeutic drugs and diagnostic tools for diabetes and inflammatory diseases. Their pipeline includes BTI-320 for blood glucose reduction, IPOXYN for necrosis prevention, and ARIA for cardiovascular risk assessment, positioning them in the competitive medical device and therapeutics market.
What Is the Investment Thesis for NNMX?
Nanomix Corporation presents a high-risk, high-reward investment opportunity. The company's pipeline of therapeutic drugs and diagnostic tools targeting diabetes and inflammatory diseases offers significant potential, particularly BTI-320 and IPOXYN, both in Phase II clinical trials. Successful completion of these trials and subsequent commercialization could drive substantial revenue growth. However, the company's negative profit margin of -79825.1% and gross margin of -449.6% highlight the significant financial challenges. The company's reliance on OTC markets also adds risk. The company's small market capitalization of $0.00B indicates a high degree of volatility and sensitivity to market conditions. Upcoming clinical trial results for BTI-320 and IPOXYN will be critical catalysts. Investors should carefully weigh the potential upside against the inherent risks associated with investing in a small, development-stage pharmaceutical company.
Based on FMP financials and quantitative analysis
NNMX Key Highlights
Market capitalization of $0.00B reflects the company's small size and potential volatility.
- Negative P/E ratio of -0.00 indicates the company is currently not profitable.
- Profit margin of -79825.1% highlights significant financial challenges and operational inefficiencies.
- Gross margin of -449.6% suggests the cost of goods sold significantly exceeds revenue.
- Beta of 0.36 indicates lower volatility compared to the overall market.
Who Are NNMX's Competitors?
NNMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNMX's Key Strengths?
Pipeline of therapeutic drugs and diagnostic tools targeting unmet medical needs.
- Proprietary drug formulations and diagnostic technologies.
- Experienced management team with expertise in drug development and commercialization.
- Focus on diabetes and inflammatory diseases, areas of significant market demand.
What Are NNMX's Weaknesses?
Limited financial resources and reliance on external funding.
- Negative profit margin and gross margin.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Small market capitalization and potential volatility.
What Could Drive NNMX Stock Higher?
Results from Phase II clinical trials for BTI-320 for blood glucose reduction.
- Results from Phase II clinical trials for IPOXYN for necrosis prevention.
- Potential strategic partnerships with larger pharmaceutical companies.
- Development and expansion of ARIA diagnostic device market reach.
- Progress in clinical trials for BTI-410 for beta cell maturation.
What Are the Key Risks for NNMX?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes for BTI-320 and IPOXYN.
- Regulatory hurdles and delays in obtaining approvals for drug candidates.
- Competition from established pharmaceutical companies and biotech firms.
- Limited financial resources and reliance on external funding.
- Economic downturn and reduced healthcare spending.
What Are the Growth Opportunities for NNMX?
- Successful completion and commercialization of BTI-320: BTI-320, a non-systemic carbohydrate-based compound tablet, is currently in Phase II clinical trials for reducing post-meal blood glucose levels in pre-diabetes and type 2 diabetes patients. The global market for diabetes treatments is estimated to reach $160 billion by 2027. Positive trial results and subsequent regulatory approval could drive significant revenue growth for Nanomix, positioning it as a key player in the diabetes management market. The timeline for potential commercialization is estimated at 2-3 years, pending successful trial outcomes and regulatory approvals.
- Advancement of IPOXYN for necrosis prevention: IPOXYN, an injectable drug designed to prevent necrosis and treat hypoxic conditions, represents another significant growth opportunity. The market for wound care and tissue repair is estimated at $22 billion globally. Successful clinical trials and commercialization of IPOXYN could address a critical unmet need in treating diabetic foot ulcers and other vascular complications, providing a substantial revenue stream for Nanomix. The timeline for potential commercialization is estimated at 3-4 years, pending successful trial outcomes and regulatory approvals.
- Development and commercialization of BTI-410: BTI-410, a peptide injectable compound in Phase II clinical trials to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery, represents a long-term growth opportunity. The market for insulin-producing cell agents is nascent but holds significant potential. Successful development and commercialization of BTI-410 could revolutionize diabetes treatment, providing a substantial revenue stream for Nanomix. The timeline for potential commercialization is estimated at 5-7 years, pending successful trial outcomes and regulatory approvals.
- Expansion of ARIA diagnostic device for cardiovascular risk assessment: The ARIA diagnostic device for screening cardiovascular risk, such as stroke, offers a growth opportunity in the diagnostic market. The global market for cardiovascular diagnostic devices is estimated at $30 billion. Expanding the market reach and adoption of ARIA could generate a steady revenue stream for Nanomix. The timeline for potential expansion is estimated at 1-2 years, focusing on strategic partnerships and market penetration.
- Strategic partnerships and collaborations: Nanomix can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its products. Collaborations can provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. The timeline for establishing strategic partnerships is ongoing, with potential deals occurring within the next 1-2 years.
What Are NNMX's Competitive Advantages?
- Proprietary drug formulations and diagnostic technologies.
- Patent protection for key products and processes.
- Clinical data supporting the efficacy and safety of drug candidates.
- Established relationships with healthcare providers and research institutions.
What Does NNMX Do?
Nanomix Corporation, formerly known as Boston Therapeutics, Inc., is a pharmaceutical and medical device company dedicated to addressing unmet medical needs in diabetes and inflammatory diseases. The company was founded with the goal of developing innovative therapies and diagnostic tools to improve patient outcomes. Their lead product candidate, BTI-320, is a non-systemic carbohydrate-based compound tablet currently in Phase II clinical trials for reducing post-meal blood glucose levels in pre-diabetes and type 2 diabetes patients. This oral drug aims to reduce the absorption of glucose after meals, offering a novel approach to managing blood sugar levels. Another key product in development is IPOXYN, an injectable drug designed to prevent necrosis and treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. IPOXYN aims to improve oxygen delivery to tissues, promoting healing and preventing tissue damage. Nanomix is also developing BTI-410, a peptide injectable compound in Phase II clinical trials to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery. Additionally, the company offers SUGARDOWN, a non-systemic polysaccharide-based dietary supplement to support healthy blood glucose levels, and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. The company's diagnostic product, ARIA (automatic retinal image analysis), is a device for screening cardiovascular risk, such as stroke, through retinal imaging. Headquartered in Lawrence, Massachusetts, Nanomix Corporation aims to provide comprehensive solutions for managing diabetes and related complications.
What Products and Services Does NNMX Offer?
- Develop therapeutic drugs for diabetes and inflammatory diseases.
- Manufacture and commercialize pharmaceutical products.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Develop diagnostic devices for cardiovascular risk assessment.
- Offer dietary supplements to support healthy blood glucose levels.
- Provide veterinary medicine applications for oxygen delivery.
How Does NNMX Make Money?
- Develop and patent novel therapeutic drugs and diagnostic tools.
- Conduct clinical trials to obtain regulatory approvals.
- Manufacture and market products directly or through partnerships.
- Generate revenue through product sales and licensing agreements.
What Industry Does NNMX Operate In?
Nanomix Corporation operates in the competitive medical device and pharmaceutical industry, focusing on diabetes and inflammatory diseases. The market for diabetes treatments is substantial and growing, driven by the increasing prevalence of diabetes globally. Competitors include established pharmaceutical companies and smaller biotech firms developing novel therapies. The company's success depends on its ability to navigate regulatory hurdles, secure funding, and effectively commercialize its products. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Nanomix must differentiate itself through innovative products and strategic partnerships to gain market share.
Who Are NNMX's Key Customers?
- Patients with diabetes and inflammatory diseases.
- Healthcare providers and hospitals.
- Veterinarians and animal healthcare facilities.
- Research institutions and pharmaceutical companies (potential partners).
Key Financial Metrics
Return on equity for Nanomix Corporation stands at 128.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Nanomix Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lawrence, US. The company is led by CEO David Gerald Ludvigson. NNMX has traded publicly since 2021.
Financial Health
Nanomix Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
The most recent 12 insider filings for Nanomix Corporation break down as 1 sales and 11 purchases. On net that is roughly 2.7M shares acquired (about $117K) — insiders putting money in tends to read as conviction.
NNMX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Pipeline of therapeutic drugs and diagnostic tools targeting unmet medical needs.
- Proprietary drug formulations and diagnostic technologies.
- Experienced management team with expertise in drug development and commercialization.
- Focus on diabetes and inflammatory diseases, areas of significant market demand.
Bear Case
- Limited financial resources and reliance on external funding.
- Negative profit margin and gross margin.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Small market capitalization and potential volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NNMX Latest News
No recent news available for NNMX.
NNMX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NNMX.
Price Targets
Wall Street price target analysis for NNMX.
NNMX MoonshotScore
What does this score mean?
The MoonshotScore rates NNMX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Gerald Ludvigson
CEO
David Gerald Ludvigson serves as the CEO of Nanomix Corporation. His background includes extensive experience in managing and leading companies, with a focus on strategic growth and operational efficiency. He has a proven track record in various leadership roles, demonstrating his ability to drive company performance and value. His expertise spans across different sectors, providing him with a broad perspective on business challenges and opportunities. He is responsible for overseeing the company's strategic direction and ensuring its long-term success.
Track Record: Under David Gerald Ludvigson's leadership, Nanomix Corporation has focused on advancing its clinical pipeline and exploring strategic partnerships. Key milestones include the progression of BTI-320 and IPOXYN through Phase II clinical trials. He has also emphasized operational improvements and cost management to address the company's financial challenges. His tenure has been marked by efforts to enhance shareholder value and position the company for future growth.
NNMX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nanomix Corporation may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review audited financial statements (if available).
- Assess the company's management team and their track record.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation for several years.
- Pipeline of therapeutic drugs and diagnostic tools in development.
- Management team with experience in the healthcare industry.
- Company has patents for key products and technologies.
Nanomix Corporation Healthcare Stock: Key Questions Answered
What does Nanomix Corporation do?
Nanomix Corporation is a healthcare company focused on developing and commercializing therapeutic drugs and diagnostic tools for diabetes and inflammatory diseases. Their pipeline includes BTI-320, a non-systemic carbohydrate-based compound tablet in Phase II clinical trials for reducing post-meal blood glucose levels in pre-diabetes and type 2 diabetes patients.
What do analysts say about NNMX stock?
As of 2026-03-16, there is no readily available analyst consensus on NNMX stock due to its small market capitalization and OTC listing. Key valuation metrics such as P/E ratio (-0.00) and profit margin (-79825.1%) indicate that the company is currently not profitable. Growth considerations revolve around the successful completion of clinical trials and commercialization of its drug candidates.
What are the main risks for NNMX?
The main risks for Nanomix Corporation include the potential for unsuccessful clinical trial outcomes for its drug candidates, regulatory hurdles and delays in obtaining approvals, competition from established pharmaceutical companies, limited financial resources and reliance on external funding, and the inherent risks associated with investing in OTC stocks. The company's negative profit margin and gross margin highlight its financial challenges. Investors should carefully weigh these risks before investing in NNMX.
How does Nanomix Corporation navigate regulatory approval processes?
Nanomix Corporation navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its drug candidates. The company works closely with regulatory agencies such as the FDA to ensure compliance with all applicable regulations and guidelines. They also maintain a strong focus on data integrity and quality control throughout the clinical trial process.
What is Nanomix Corporation's drug pipeline status?
Nanomix Corporation's drug pipeline includes BTI-320, a non-systemic carbohydrate-based compound tablet in Phase II clinical trials for reducing post-meal blood glucose levels in pre-diabetes and type 2 diabetes patients. IPOXYN, an injectable drug to prevent necrosis and treat hypoxic conditions, is also in Phase II clinical trials.
What are the key factors to evaluate for NNMX?
Evaluate NNMX on fundamentals, analyst consensus, and risk factors. Nanomix Corporation presents a high-risk, high-reward investment opportunity. Not financial advice.
How frequently does NNMX data refresh on this page?
NNMX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NNMX's recent stock price performance?
Nanomix Corporation (NNMX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of therapeutic drugs and diagnostic tools targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.